Acrivon Therapeutics, Inc. (ACRV) Stock Price & Analysis
Acrivon Therapeutics, Inc. (ACRV) fell 4.19% to USD 1.6 as of July 26, 2026 at 09:20 UTC, according to Nexqual real-time market data.
ACRV last closed at USD 1.67; the session ranged USD 1.6–1.68 on volume of 257,675 shares. Market capitalization is $68.48M, with a 52-week range of USD 1.2–3.56 (NGM). Source: Nexqual, July 26, 2026 at 09:20 UTC.
Key Statistics (as of July 26, 2026 at 09:20 UTC)
| Price | USD 1.6 |
|---|---|
| Change | ▼ 4.19% (down) |
| Previous Close | USD 1.67 |
| Open | USD 1.68 |
| Day Range | USD 1.6 – 1.68 |
| 52-Week Range | USD 1.2 – 3.56 |
| Volume | 257,675 shares |
| Market Cap | $68.48M |
| Exchange | NGM |
Technical Analysis (ACRV)
Nexqual's technical model rates ACRV "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 09:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.55 (neutral) |
| vs SMA50 | Below (USD 1.69) |
| MACD | 0 (positive) |
Analyst Ratings (ACRV)
Wall Street analysts rate ACRV "None" based on 6 analysts, with a mean price target of USD 11.5 (range USD 7–19), per Nexqual as of July 26, 2026 at 09:20 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 11.5 |
| High Target | USD 19 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (ACRV)
| EPS Estimate | USD -0.5 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.49 vs est -0.52 ▲ beat |
| 2025-12-31 | USD -0.49 vs est -0.46 ▼ miss |
| 2025-09-30 | USD -0.47 vs est -0.58 ▲ beat |
| 2025-06-30 | USD -0.55 vs est -0.58 ▲ beat |
Source: Nexqual, July 26, 2026 at 09:20 UTC.
Financials & Fundamentals (ACRV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -60.39% |
| Debt / Equity | 2.53 |
| Current Ratio | 8.98 |
| Total Cash | $97.74M |
| Total Debt | $2.42M |
| Free Cash Flow | $-40.89M |
Source: Nexqual, July 26, 2026 at 09:20 UTC.
Financial Health Score (ACRV)
Nexqual rates Acrivon Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 09:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $98M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$65M |
| Efficiency | Critical — ROE -60%, ROA -36.2% |
Ownership (ACRV)
| Insider Ownership | +15.43% |
|---|---|
| Institutional Ownership | +47.39% |
| Shares Outstanding | 42.80M |
| Float | 27.93M |
| Short % of Float | +5.19% |
Source: Nexqual, July 26, 2026 at 09:20 UTC.
Leadership (ACRV)
Acrivon Therapeutics, Inc. is led by Peter Blume-Jensen (age 62), Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer, per Nexqual as of July 26, 2026 at 09:20 UTC.
| Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer | Peter Blume-Jensen (age 62) |
|---|---|
| Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director | Kristina Masson (age 45) |
| Chief Operating Officer | Eric J. Devroe (age 46) |
| CFO & Principal Financial Officer | Adam D. Levy (age 59) |
| Vice President of Finance & Accounting | Katharine Peterson |
Major Backers & Investors (ACRV)
Notable institutional backers of Acrivon Therapeutics, Inc. include RA Capital Management, L.P., Sands Capital Alternatives, LLC, Wellington Management, according to Nexqual as of July 26, 2026 at 09:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 19.49% |
| Sands Capital Alternatives, LLC | 4.96% |
| Wellington Management | 2.07% |
| Acadian Asset Management. LLC | 1.98% |
| Renaissance Technologies | 1.77% |
| Marshall Wace LLP | 1.31% |
| Two Sigma Investments, LP | 0.91% |
| Jane Street Group, LLC | 0.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.37% |
| Geode Capital | 0.55% |
Source: Nexqual, July 26, 2026 at 09:20 UTC.
From Acrivon Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
- The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
- Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer.
- The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PEPG | PepGen Inc. | USD 1.93 | ▲ 0.52% |
| RLYB | Rallybio Corporation | USD 16.31 | ▼ 1.87% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 22.78 | ▼ 4.25% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.13 | ▼ 3.62% |
| TCRX | TScan Therapeutics, Inc. | USD 0.79 | ▼ 11.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 09:20 UTC. This page is informational and not investment advice.